The pharmaceutical industry is on the brink of massive transformation driven by cutting-edge technology and strategic ...

Industry veteran with a 30-year track record in building award-winning clinical and commercial technologies, Hodgins will focus on developing and enriching transformative technologies across ...

A new multimodal tool combines a large language model with powerful graph-based AI models to efficiently find new, synthesizable molecules with desired properties, based on a user's queries in plain ...

Industry veteran with a 30-year track record in building award-winning clinical and commercial technologies, Hodgins will focus on developing and enriching transformative technologies across Precision ...

During a recent panel discussion sponsored by Purdue University, industry leaders explain how the technology is revolutionizing drug development and production ...

Imports, meanwhile, increased by just 0.5 per cent to €119.7 billion. This resulted in a record trade surplus of €193.6 billion for the bloc. Germany was the largest extra-EU exporter, with ...

The Trump administration can push back using the same trade mechanisms it employs in other sectors. America invents the majority of the world's new medicines -- yet we ran a $117 billion global ...

The three clinics that closed had been subsidized within the overall Waco Family Medicine system, Griggs said. “With the impact of Texas Medicaid policies and they way pharmacy benefit managers ...

Sri Lanka’s pharma supply is 85% import-dependent. The cost of medicines: >35% of annual health budget [18% in countries of the Organization for Economic Cooperation and Development (OECD)] Sri Lanka ...

The sector has bounced back from a difficult 2024 and is set to grow significantly, thanks to developments in AI-driven drug discovery, personalized medicine, and the rising demand for biologics.

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. Good morning, everyone, and welcome to another working week.

Bringing a medicine into a developing country where there is limited or no paying power is an immense challenge. For a pharmaceutical company, it is not business as usual. Market access in ...